LOS ANGELES, Aug. 29, 2017 /PRNewswire/ -- Global Health Solutions, a Georgia based biotechnology company engaged in the development of novel, topical therapeutic agents for chronic wounds and dermatologic conditions, has announced FDA clearance of AtopX™ Emulsion, indicated for the management of atopic, irritant, and radiation dermatitis. AtopX™ employs Global Health Solutions' proprietary delivery technology, PermaFusion™, first showcased in its groundbreaking chronic wound care products.
Atopic dermatitis, commonly known as eczema, is a chronic condition that affects nearly 18 million children and adults in the United States. Global Health Solutions' Founder and CEO, Bradley Burnam, states: "Eczema is a systemic condition. The goal of topical therapy in the management of eczema should focus entirely on symptom management and skin repair. AtopX™ has shown dramatic effectiveness in early clinical results, along with a safety profile rivaling even over-the-counter options." Neil Ghodadra, MD, Global Health Solutions' Chief Medical Officer, discusses AtopX™: "Eczema is an incredibly pervasive, stubborn condition, with limited non-steroidal options. AtopX™ will provide physicians a safe, cost-effective, topical solution that creates an ideal healing environment for injured tissue resulting from this systemic condition."
Global Health Solutions expects AtopX™ to be well-received by practitioners and patients due to its ease of use, safety profile, and efficacy. AtopX™ has been tested and certified non-sensitizing, non-irritating, and non-cytotoxic, providing a welcome option for the delicate skin of children, who are most commonly afflicted by atopic dermatitis.
Global Health Solutions, LLC
The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.
SOURCE Global Health Solutions